CR9200A - Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos - Google Patents
Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativosInfo
- Publication number
- CR9200A CR9200A CR9200A CR9200A CR9200A CR 9200 A CR9200 A CR 9200A CR 9200 A CR9200 A CR 9200A CR 9200 A CR9200 A CR 9200A CR 9200 A CR9200 A CR 9200A
- Authority
- CR
- Costa Rica
- Prior art keywords
- agonist
- prevention
- treatment
- neurodegenerative disorders
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion suminstra un metodo para el tratamiento, mejora o prevencion de un trastorno neurodegenerativo en un paciente en necesidad de este el caul comprende administrar a dicho paciente una cantidad efectiva de un agonista de 5-hidroxitriptamina-6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63576604P | 2004-12-14 | 2004-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9200A true CR9200A (es) | 2007-09-07 |
Family
ID=36177731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9200A CR9200A (es) | 2004-12-14 | 2007-06-20 | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060128744A1 (es) |
EP (1) | EP1824464A1 (es) |
JP (1) | JP2008523146A (es) |
KR (1) | KR20070088770A (es) |
CN (1) | CN101098683A (es) |
AU (1) | AU2005316675A1 (es) |
BR (1) | BRPI0519036A2 (es) |
CA (1) | CA2590841A1 (es) |
CR (1) | CR9200A (es) |
IL (1) | IL183859A0 (es) |
MX (1) | MX2007007206A (es) |
NO (1) | NO20073104L (es) |
RU (1) | RU2007122450A (es) |
WO (1) | WO2006065710A1 (es) |
ZA (1) | ZA200705083B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
JP2005305107A (ja) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | 価値的情報値の測定装置およびこれを使用した測定方法 |
WO2007136790A2 (en) | 2006-05-18 | 2007-11-29 | Mannkind Corporation | Intracellular kinase inhibitors |
EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
CN104557664B (zh) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
ES2269827T3 (es) * | 2001-12-20 | 2007-04-01 | Wyeth | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6. |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2005
- 2005-12-12 EP EP05853687A patent/EP1824464A1/en not_active Withdrawn
- 2005-12-12 RU RU2007122450/14A patent/RU2007122450A/ru not_active Application Discontinuation
- 2005-12-12 JP JP2007546799A patent/JP2008523146A/ja not_active Withdrawn
- 2005-12-12 CN CNA2005800464202A patent/CN101098683A/zh not_active Withdrawn
- 2005-12-12 KR KR1020077015556A patent/KR20070088770A/ko not_active Application Discontinuation
- 2005-12-12 BR BRPI0519036-3A patent/BRPI0519036A2/pt not_active IP Right Cessation
- 2005-12-12 WO PCT/US2005/044820 patent/WO2006065710A1/en active Application Filing
- 2005-12-12 CA CA002590841A patent/CA2590841A1/en not_active Abandoned
- 2005-12-12 AU AU2005316675A patent/AU2005316675A1/en not_active Abandoned
- 2005-12-12 MX MX2007007206A patent/MX2007007206A/es unknown
- 2005-12-13 US US11/301,445 patent/US20060128744A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183859A patent/IL183859A0/en unknown
- 2007-06-13 ZA ZA200705083A patent/ZA200705083B/xx unknown
- 2007-06-18 NO NO20073104A patent/NO20073104L/no not_active Application Discontinuation
- 2007-06-20 CR CR9200A patent/CR9200A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2590841A1 (en) | 2006-06-22 |
EP1824464A1 (en) | 2007-08-29 |
KR20070088770A (ko) | 2007-08-29 |
BRPI0519036A2 (pt) | 2008-12-23 |
MX2007007206A (es) | 2008-03-26 |
WO2006065710A1 (en) | 2006-06-22 |
US20060128744A1 (en) | 2006-06-15 |
JP2008523146A (ja) | 2008-07-03 |
ZA200705083B (en) | 2010-03-31 |
CN101098683A (zh) | 2008-01-02 |
RU2007122450A (ru) | 2009-01-27 |
IL183859A0 (en) | 2008-12-29 |
NO20073104L (no) | 2007-07-02 |
AU2005316675A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
AR058182A1 (es) | Metodos, composiciones y equipos par el tratamiento de afecciones medicas | |
BRPI0518228A (pt) | inibidores de cinesina mitótica e métodos de uso destes | |
AR053026A1 (es) | Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf) | |
AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
CR8701A (es) | Moduladores canabinoides de tetrahidro-indazol | |
BRPI0812889A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal. | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
BRPI0511477A (pt) | compostos e composições como moduladores de ppar | |
DK1853250T3 (da) | Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi | |
HN2006000971A (es) | Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1 | |
HRP20070552T3 (en) | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
MX2007005040A (es) | Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |